European medicinal and edible plants associated with subacute and chronic toxicity part II: Plants with hepato-, neuro-, nephro- and immunotoxic effects

Food and Chemical Toxicology

Volumn 92, Issue , 2016, Pages 38-49

  Kristanc, Luka ^a,b   Kreft, Samo ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b Primary Healthcare of Gorenjska   (Slovenia)

Author keywords

European plants; Hepatotoxic; Immunosuppressive; Nephrotoxic; Neurotoxic; Thiamine depletion

Indexed keywords

ARISTOLOCHIC ACID; CANNABINOID; CANNABIS; FLAVONOID; HERBACEOUS AGENT; OXALIC ACID DERIVATIVE; PYRROLIZIDINE ALKALOID; SWAINSONINE; ANTINEOPLASTIC AGENT; CURCUMIN; DRUG CARRIER; GLUTATHIONE; HEXANOIC ACID DERIVATIVE; LACTATE DEHYDROGENASE; MALONALDEHYDE; METHACRYLIC ACID DERIVATIVE; PDMAEMA-B-PCL-B-PDMAEMA; POLYMER;

ACTAEA RACEMOSA; ACUTE HEPATITIS; CENTELLA ASIATICA; CHELIDONIUM; CHOLESTATIC HEPATITIS; CHRONIC HEPATITIS; CHRONIC TOXICITY; COMFREY; CULLEN CORYLIFOLIUM; DEPLETION; EDIBLE PLANT; EPHEDRA SINICA; EUROPE; GARDENIA JASMINOIDES; GERMANDER; GRANULOMATOUS HEPATITIS; HUMAN; HYPOTHYROIDISM; IMMUNE DEFICIENCY; IMMUNOTOXICITY; JAUNDICE; LATHYRISM; LIVER CIRRHOSIS; LIVER TOXICITY; MEDICINAL PLANT; MENTHA PULEGIUM; MOLECULAR MECHANICS; NEPHROLITHIASIS; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PETASITES; PIPER METHYSTICUM; POLYGONATUM MULTIFLORUM; PORTAL HYPERTENSION; REVIEW; SABAL; SCUTELLARIA; SENECIO; SENNA ALEXANDRINA; TEUCRIUM CHAMAEDRYS; THIAMINE DEPLETION; THYROID DISEASE; VALERIANA OFFICINALIS; VISCUM ALBUM; ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HEP-G2 CELL LINE; MALE; METABOLISM; OXIDATIVE STRESS; RAT; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CAPROATES; CELL SURVIVAL; CURCUMIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GLUTATHIONE; HEP G2 CELLS; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MALONDIALDEHYDE; METHACRYLATES; OXIDATIVE STRESS; POLYMERS; RATS; RATS, WISTAR;

EID: 84962157102     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2016.03.014     Document Type: Review

References (208)

1. Agarwal M.M., Singh S.K., Mavuduru R., Mandal A.K. Preventive fluid and dietary therapy for urolithiasis: an appraisal of strength, controversies and lacunae of current literature. Indian J. Urol. 2011, 27:310-319.
2. Albihn P.B.E., Savage G.P. The bioavailability of oxalate from oca (Oxalis tuberosa). J. Urol. 2001, 166:420-422.
3. Ali M.N., Ali J.N., Chen P.C., Hsieh S.H., Hu F.C., Wang J.D. Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population based case-control study. Am. J. Kidney Dis. 2010, 55:507-518.
4. Andrade R.J., Lucena M.I., Fernandez M.C., Pelaez G., Pachkoria K., García-Ruiz E., García-Muñoz B., González-Grande R., Pizarro A., Durán J.A., Jiménez M., Rodrigo L., Romero-Gomez M., Navarro J.M., Planas R., Costa J., Borras A., Soler A., Salmerón J., Martin-Vivaldi R. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005, 129:512-521.
5. Arlt V.M., Stiborova M., Schmeiser H.H. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 2002, 17:265-277.
6. Badwaik H., Singh M.K., Thakur D., Giri T.K., Tripathi D.K. The botany, chemistry, pharmacological and therapeutic application of Oxalis corniculata Linn. - a review. Int. J Phytomed. 2011, 3:1-8.
7. Begaud B., Martin K., Haramburu F., Moore N. Rates of adverse drug reactions in France [Letter]. JAMA 2002, 288:1588.
8. Beuers U., Spengler U., Pape G. Hepatitis after chronic abuse of senna. Lancet 1991, 337:372-373.
9. Bjornsson E.S., Bergmann O.M., Bjornsson H.K., Kvaran R.B., Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013, 144:1419-1425.
10. Bodeker C., Bodeker G., Ong C.K., Grundy C.K., Burford G., Shein K. WHO Global Atlas of Traditional, Complementary and Alternative Medicine 2005, WHO, Geneva, Switzerland.
11. Bodi D., Ronczka S., Gottschalk C., Behr N., Skibba A., Wagner M., Lahrssen-Wiederholt M., Preiss-Weigert A., These A. Determination of pyrrolizidine alkaloids in tea, herbal drugs and honey. Food Addit. Contam. 2014, 31:1886-1895.
12. Borum M.L. Fulminant exacerbation of autoimmune hepatitis after the use of ma huang. Am. J. Gastroenterol. 2001, 96:1654-1655.
13. Braun L.A., Tiralongo E., Wilkinson J.M., Spitzer O., Bailey M., Poole S. Michael Dooley. Perceptions, use and attitudes of pharmacy customers on complementary medicines and pharmacy practice. BMC Complement. Altern. Med. 2010, 10:38.
14. Brogren M., Savage G.P. Bioavailability of soluble oxalate from spinach eaten with and without milk products. Asia Pac. J. Clin. Nutr. 2003, 12:219-224.
15. Bunchorntavakul C., Reddy K.R. Review article: herbal and dietary supplement hepatotoxicity. Aliment. Pharmacol. Ther. 2013, 37:3-17.
16. Calapai G. European legislation on herbal medicines: a look into the future. Drug Saf. 2008, 31:428-431.
17. Calvo R., Obregon M.J., Ruiz de Oña C., Escobar del Rey F., Morreale de Escobar G. Congenital hypothyroidism, as studied in rats. Crucial role of maternal thyroxine but not of 3,5,30-triiodothyronine in the protection of the fetal brain. J. Clin. Investig. 1990, 86:889-899.
18. Castot A., Larrey D. Hepatitis observed during a treatment with a drug or tea containing Wild Germander. Evaluation of 26 cases reported to the Regional centers of pharmacovigilance. Gastroenterol. Clin. Biol. 1992, 16:916-922.
19. Chai W., Liebman M. Assessment of oxalate absorption from almonds and black beans with and without the use of an extrinsic label. J. Urol. 2004, 172:953-957.
20. Chalasani N., Fontana R.J., Bonkovsky H.L., Watkins P.B., Davern T., Serrano J., Yang H., Rochon J. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 135:1924-1934.
21. Chandra A.K., Mukhopadhyay S., Lahari D., Tripathy S. Goitrogenic content of Indian cyanogenic plant foods and their in vitro anti-thyroidal activity. Indian J. Med. Res. 2004, 119:180-185.
22. Chandra A.K., Singh L.H., Ghosh S., Pearce E.N. Role of bamboo-shoot in the pathogenesis of endemic goiter in manipur, north East India. Endocr. Pract. 2013, 19:36-45.
23. Chen X.-W., Serag E.S., Sneed K.B., Zhou S.-F. Herbal bioactivation, molecular targets and the toxicity relevance. Chem. Biol. Interact. 2011, 192:161-176.
24. Chen C.H., Dickman K.G., Moriya M., Zavadil J., Sidorenko V.S., Edwards K.L., Gnatenko D.V., Wu L., Turesky R.J., Wu X.-R., Pu Y.-S., Grollman A.P. Aristolochic acid-associated urothelial cancer in Taiwan. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:8241-8246.
25. Chenchen W., Wenlong W., Xiaoxue L., Feng M., Dandan C., Xiaowen Y., Shanshan W., Pengshuai G., Hao L., Baoy Z. Pathogenesis and preventive treatment for animal disease due to locoweed poisoning. Environ. Toxicol. Pharmacol. 2014, 37:336-347.
26. Chow E.C., Teo M., Ring J.A., Chen J.W. Liver failure associated with the use of black cohosh for menopausal symptoms. Med. J. Aust. 2008, 188:420-422.
27. Cohen S.M., O'Connor A.M., Hart J., Merel N.H., Te H.S. Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause 2004, 11:575-577.
28. Colegate S.M., Dorling P.R., Huxtable C.R. A spectroscopic investigation of swainsonine: an alpha-mannosidase inhibitor isolated from Swainsona canescens (a plant poisonous to livestock). Aust. J. Chem. 1979, 32:2257-2264.
29. Combs G.F. The vitamins: fundamental aspects in nutrition and health 2008, Elsevier Academic Press, Ithaca, NY.
30. Cook D., Ralphs M.H., Welch K.D., Stegelmeier B.L. Locoweed poisoning in livestock. Rangelands 2009, 31:16-21.
31. Cosyns J.P., Jadoul M., Squifflet J.P., Wese F., De Strihou C.V.Y. Urothelial lesions in Chinese-herb nephropathy. Am. J. Kidney Dis. 1999, 33:1011-1017.
32. Coulombe R.A. Pyrrolizidine alkaloids in food. Adv. Food Nutr. Res. 2003, 45:61-99.
33. Cramer L., Ernst L., Lubienski M., Papke U., Schiebel H.M., Jerz G., Beuerle T. Structural and quantitative analysis of Equisetum alkaloids. Phytochemistry 2015, 116:269-282.
34. Croxford J.L. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 2003, 17(3):179-202.
35. Croxford J.L., Yamamura T. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases?. J. Neuroimmunol. 2005, 166(1-2):3-18.
36. Cuevas A., Saavedra N., Salazar L.A., Abdalla D.S.P. Modulation of immune function by polyphenols: possible contribution of epigenetic factors. Nutrients 2013, 5:2314-2332.
37. D'Adamo C.R., Sahin A. Soy foods and supplementation: a review of commonly perceived health benefits and risks. Altern. Ther. Health Med. 2014, 20:39-51.
38. Da H.Y., Jiang Z.Z., Wang C.F., Zhang L.Y., Liu G.Q. The toxic effects of rhein and emodin on human renal tubular epithelial cells in vitro. Chin. Trad. Herb. Drugs 2009, 40:102-105.
39. Dantas A.F.M., Riet-Correa F., Gardner D.R., Medeiros R.M., Barros S.S., Anjos B.L., Lucena R.B. Swainsonine-induced lysosomal storage disease in goats caused by the ingestion of Turbina cordata in northeastern. Braz. Toxicon 2007, 49:111-116.
40. Das P.C., Roberts J.D., White S.L., Olden K. Activation of resident tissue-specific macrophages by swainsonine. Oncol. Res. 1995, 7:425-433.
41. De Jonge H., Vanrenterghem Y. Aristolochic acid: the common culprit of Chinese herbs nephropathy and Balkan endemic nephropathy. Nephrol. Dial. Transpl. 2008, 23:39-41.
42. De Mendonça C., Martini L.A., Baxmann A.C., Nishiura J.L., Cuppari L., Sigulem D.M., Heilberg I.P. Effects of an oxalate load on urinary oxalate excretion in calcium stone formers. J. Ren. Nutr. 2003, 13:39-46.
43. Debelle F.D., Nortier J.L., de Prez E.G., Garbar C.H., Vienne A.R., Salmon I.J., Deschodt-Lanckman M.M., Vanherweghem J.L. Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt depleted rats. J. Am. Soc. Nephrol. 2002, 13:431-436.
44. Debelle F.D., Vanherweghem J., Nortier J.L. Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 2008, 74:158-169.
45. DeLeve L.D., McCuskey R.S., Wang X., Hu L., McCuskey M.K., Epstein R.B., Kanel G.C. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology 1999, 29:1779-1791.
46. DeLeve L.D., Shulman H.M., McDonald G.B. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin. Liver Dis. 2002, 22:27-41.
47. Drew A.K., Whyte I.M., Bensoussan A., Dawson A.H., Zhu X., Myers S.P. Chinese herbal medicine toxicology database: monograph on herba asari, 'xi xin'. J. Toxicol. 2002, 40(2):169-172.
48. Edgar J.A. Pyrrolizidine alkaloids and food safety. Chem. Austral. 2003, 70:4-7.
49. Edgar J.A., Colegate S.M., Boppré M., Molyneux R.J. Pyrrolizidine alkaloids in food: a spectrum of potential health consequences. Food Addit. Contam. 2011, 28:308-324.
50. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front. Pharmacol. 2014, 177:1-10.
51. El-Gohary M., Eid M.A. Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students. Hum. Exp. Toxicol. 2004, 23:149-156.
52. Enneking D. The nutritive value of grasspea (Lathyrus sativus) and allied species, their toxicity to animals and the role of malnutrition in neurolathyrism. Food Chem. Toxicol. 2011, 49:694-709.
53. Estes J.D., Stolpman D., Olyaei A., Corless C.L., Ham J.M., Schwartz J.M., Orloff S.L. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch. Surg. 2003, 138:852-858.
54. Facciola S. Cornucopia - a source book of edible plants 1990, Kampong Publications, Nature, 677 pp.
55. Farah M.H., Edwards I.R., Lindquist M., Leon C., Shaw D. International monitoring of adverse health effects associated with herbal medicines. Pharmacoepidemiol Drug Saf. 2000, 9:105-112.
56. Fridman J.S., Lowe S.W. Control of apoptosis by p53. Oncogene 2003, 22:9030-9040.
57. Fu P.P., Xia Q., Lin G., Chou M.W. Pyrrolizidine alkaloids - genotoxicity, metabolism enzymes, metabolic activation and mechanisms. Drug Metab. Rev. 2004, 36:1-55.
58. Gaitan E., Lindsay R.H., Reichert R.D., Ingbar S.H., Cooksey R.C., Legan J., Meydrech E.F., Hill J., Kubota K. Antithyroid and goitrogenic effects of millet: role of C-glycosylflavones. J. Clin. Endocrinol. Metab. 1989, 68:707-714.
59. Gao X.L., Cook D., Ralphs M.H., Yan L., Gardner D.R., Lee S.T., Panter K.E., Han B., Zhao M.L. Detection of swainsonine and isolation of the endophyte Undifilum from the major locoweeds in Inner Mongolia. Biochem. Syst. Ecol. 2012, 45:79-85.
60. Gilbert M.E., Rovet J., Chen Z., Koibuchi N. Developmental thyroid hormone disruption: prevalence, environmental contaminants and neurodevelopmental consequences. Neurotoxicology 2012, 33:842-852.
61. Gilman A.G., Rall T.W., Nies A.S., Taylor P. Goodman and Gilman's The Pharmacological Basis of Therapeutics 1990, Pergamon Press, New York.
62. Glew R.H., Sun Y., Horowitz B.L., Konstantinov K.N., Barry M., Fair J.R., Massie L., Tzamaloukas A.H. Nephropathy in dietary hyperoxaluria: a potentially preventable acute or chronic kidney disease. World J. Nephrol. 2014, 3(4):122-142.
63. Gori L., Galluzzi P., Mascherini V., Gallo E., Lapi F., Menniti-Ippolito F., Raschetti R., Mugelli A., Vannacci A., Firenzuoli F. Two contemporary cases of hepatitis associated with Teucrium chamaedrys L. decoction use: case reports and review of literature. Basic Clin. Pharmacol. Toxicol. 2011, 109:521-526.
64. Gostner J., Ciardi C., Becker K., Fuchs D., Sucher R. Immunoregulatory impact of food antioxidants. Curr. Pharm. Des. 2014, 20:840-849.
65. Grant I., Cahn B.R. Cannabis and endocannabinoid modulators: therapeutic promises and challenges. Clin. Neurosci. Res. 2005, 5(2-4):185-199.
66. Grollman A.P., Jelaković B. Role of environmental toxins in endemic (Balkan) nephropathy. J. Am. Soc. Nephrol. 2007, 18:2817-2823.
67. Grollman A.P., Shibutani S., Moriya M., Miller F., Wu L., Moll U., Suzuki N., Fernandes A., Rosenquist T., Medverec Z., Jakovina K., Brdar B., Slade N., Turesky R.J., Goodenough A.K., Rieger R., Vukelić M., Jelaković B. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12129-12134.
68. Guo L., Liu W., Lu T., Guo W., Gao J., Luo Q., Wu X., Sun Y., Wu X., Shen Y., Xu Q. Decrease of functional activated T and B cells and treatment of glomerulonephitis in lupus-prone mice using a natural flavonoid astilbin. PLoS One 2015, 10(4):e0124002.
69. Guzman M. Cannabinoids: potential anticancer agents. Nat. Rev. Cancer 2003, 3(10):745-755.
70. Jain R.K., Junaid M.A., Rao S.L. Receptor interactions of β-N-oxalyl-L-α,β-diaminopropionic acid, the Lathyrus sativus putative excitotoxin, with synaptic membrances. Neurochem. Res. 1998, 23:1191-1196.
71. Haimanot R.T., Kidane Y., Wuhib E., Kalissa A., Alemu T., Zein Z.A., Spencer P.S. Lathyrism in rural northwestern Ethiopia: a highly prevalent neurotoxic disorder. Int. J. Epidemiol. 1990, 19:664-672.
72. Hamid S., Rojter S., Vierling J. Protracted cholestatic hepatitis after the use of prostata. Ann. Intern Med. 1997, 127:169-170.
73. Hanson C.F., Frankos V.H., Thompson W.O. Bioavailability of oxalic acid from spinach, sugar beet fibre and a solution of sodium oxalate consumed by female volunteers. Food Chem. Toxicol. 1989, 27:181-184.
74. Hardeman E., Van Overbeke L., Ilegems S., Ferrante M. Acute hepatitis induced by greater celandine (Chelidonium majus). Acta Gastroenterol. Belg. 2008, 71:281-282.
75. Hashimoto K., Higuchi M., Makino B., Sakakibara I., Kubo M., Komatsu Y., Maruno M., Okada M. Quantitative analysis of aristolochic acids, toxic compounds, contained in some medicinal plants. J. Ethnopharmacol. 1999, 64:185-189.
76. Hiramatsu K., Sakata H., Horita Y., Orita N., Kida A., Mizukami A., Miyazawa M., Hirai S., Shimatani A., Matsuda K., Matsuda M., Ogino H., Fujinaga H., Terada I., Shimizu K., Uchiyama A., Ishizawa S., Abo H., Demachi H., Noda Y. Mesenteric phlebosclerosis associated with long-term oral intake of geniposide, an ingredient of herbal medicine. Aliment. Pharmacol. Ther. 2012, 36:575-586.
77. Holmes R.P., Assimos D.G. The impact of dietary oxalate on kidney stone formation. Urol. Res. 2004, 32:311-316.
78. Holmes R.P., Goodman H.O., Assimos D.G. Dietary oxalate and its intestinal absorption. Scanning Microsc. 1995, 9:1109-1120.
79. Howlett A.C., Johnson M.R., Melvin L.S., Milne G.M. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol. Pharmacol. 1988, 33(3):297-302.
80. Hueza I.M., Guerra J.L., Haraguchi M., Naoki A., Górniak S.L. The role of alkaloids in Ipomoea carnea toxicosis: a study in rats. Exp. Toxicol. Pathol. 2005, 57:53-58.
81. Hullar T.E., Sapers B.L., Ridker P.M., Jenkins R.L., Huth T.S., Farraye F.A. Herbal toxicity and fatal hepatic failure. Am. J. Med. 1999, 106:267-268.
82. Huxtable C.R., Dorling P.R. Mannoside storage and axonal dystrophy in sensory neurones of swainsonine-treated rats: morphogenesis of lesions. Acta Neuropathol. 1985, 68:65-73.
83. Ibanez L., Perez E., Vidal X., Laporte J.R. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J. Hepatol. 2002, 37:592-600.
84. International Programme on Chemical Safety (IPCS) Pyrrolizidine Alkaloids: Health and Safety Guide No. 26; WHO 1989, Switzerland, Geneva.
85. Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J. Clin. 2002, 52(2):72-91.
86. Ivić M. Etiology of endemic nephropathy. Lijec. Vjesn. (in Serbian) 1969, 91:1273-1281.
87. Jan T.R., Su S.T., Wu H.Y., Liao M.H. Suppressive effects of cannabidiol on antigen-specific antibody production and functional activity of splenocytes in ovalbumin-sensitized BALB/c mice. Int. Immunopharmacol. 2007, 7:773-780.
88. Jelaković B., Karanović S., Vuković-Lela I., Miller F., Edwards K.L., Nikolić J., Tomić K., Slade N., Brdar B., Turesky R.J., Stipančić Ž., Dittrich D., Grollman A.P., Dickman K.G. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int. 2012, 81:559-567.
89. Jhade D., Ahirwar D., Jain R., Sharma N., Gupta S. Pharmacognostic standardization, physico- and phytochemical evaluation of Amaranthus spinosus Linn. Root. J. Young Pharm. 2011, 3(3):221-225.
90. Johnson B.M., Qiu S.X., Zhang S., Zhang F., Burdette J.E., Yu L., Bolton J.L., van Breemen R.B. Identification of novel electrophilic metabolites of Piper methysticum Forst (Kava). Chem. Res. Toxicol. 2003, 16:733-740.
91. Jong T.T., Lee M.R., Hsiao S., Hsai J.L., Wu T.S., Chiang S.T., Cai S.Q. Analysis of aristolochic acid in nine sources of Xixin, a traditional Chinese medicine, by liquid chromatography/atmospheric pressure chemical ionization/tandem mass spectrometry. J. Pharm. Biomed. Anal. 2003, 33(4):831-837.
92. Jorge O.A., Jorge A.D. Hepatotoxicity associated with the ingestion of Centella asiatica. Rev. Esp. Enferm. Dig. 2005, 97:115-124.
93. Kaplan B.L.F. The role of CB1 in immune modulation by cannabinoids. Pharmacol. Ther. 2013, 137:365-374.
94. Klein T.W., Cabral G.A. Cannabinoid-induced immune suppression and modulation of antigen presenting cells. J. Neuroimmun. Pharmacol. 2006, 1(1):50-64.
95. Klein T.W., Newton C.A., Friedman H. Cannabinoid receptors and immunity. Immunol. Today 1998, 19(8):373-381.
96. Klein T.W., Lane B., Newton C.A., Friedman H. The cannabinoid system and cytokine network. Proc. Soc. Exp. Biol. Med. 2000, 225(1):1-8.
97. Konishi T., Ichijo S. Experimentally induced equine bracken poisoning by thermostable antithiamine factor (SF factor) extracted from dried bracken. J. Jpn. Vet. Med. Assoc. 1984, 37:730-734.
98. Kumar R.N., Chambers W.A., Pertwee R.G. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia 2001, 56(11):1059-1068.
99. Künig G., Hartmann J., Niedermeyer B., Deckert J., Ransmayr G., Heinsen H., Beckmann H., Riederer P. Excitotoxins L-beta-oxalyl-amino-alanine (L-BOAA) and 3,4,6-trihydroxyphenylalanine (6-OHDOPA) inhibit [3H] alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) binding in human hippocampus. Neurosci. Lett. 1994, 169:219-222.
100. Kusama-Eguchi K., Yamazaki Y., Ueda T., Suda A., Hirayama 11 Y., Ikegami F., et al. Hind-limb paraparesis in a rat model for neurolathyrism associated with apoptosis and an impaired vascular endothelial growth factor system in the spinal cord. J. Comp. Neurol. 2010, 518:928-942.
101. Kusama-Eguchi K., Yoshino N., Minoura A., Watanabe K., Kusama T., Lambein F. Sulfur amino acids deficiency caused by grass pea diet plays an important role in the toxicity of L-β-ODAP by increasing the oxidative stress: studies on a motor neuron cell line. Food Chem. Toxicol. 2011, 49:636-643.
102. Laliberte L., Villeneuve J.P. Hepatitis after the use of germander, a herbal remedy. CMAJ 1996, 154:1689-1692.
103. Lapi F., Gallo E., Giocaliere E., Vietri M., Baronti R., Pieraccini G., Tafi A., Menniti-Ippolito F., Mugelli A., Firenzuoli F., Vannacci A. Acute liver damage due to Serenoa repens: a case report. Br. J. Clin. Pharmacol. 2010, 69:558-560.
104. Larrey D., Faure S. Herbal medicine hepatotoxicity: a new step with development of specific biomarkers. J. Hepatol. 2011, 54:599-601.
105. Larrey D., Vial T., Pauwels A., Castot A., Biour M., David M., Michel H. Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann. Intern Med. 1992, 117:129-132.
106. Lather A., Valecha R., Sharma K., Garg M. World wide potential of plants causing teratogenicity - an overview. Spatula DD 2011, 1:101-106.
107. Lekehal M., Pessayre D., Lereau J.M., Moulis C., Fouraste I., Fau D. Hepatotoxicity of the herbal medicine germander: metabolic activation of its furano diterpenoids by cytochrome P450 3A depletes cytoskeleton associated protein thiols and forms plasma membrane blebs in rat hepatocytes. Hepatology 1996, 24:212-218.
108. Leleu-Chavain N., Desreumaux P., Chavatte P., Millet R. Therapeutical potential of CB2 receptors in immune-related diseases. Curr. Mol. Pharmacol. 2013, 6:183-203.
109. Levitsky J., Alli T.A., Wisecarver J., Sorrell M.F. Fulminant liver failure associated with the use of black cohosh. Dig. Dis. Sci. 2005, 50:538-539.
110. Liebman M., Al-Wahsh I.A. Probiotics and other key determinants of dietary oxalate absorption. Adv. Nutr. 2011, 2(3):254-260.
111. Lin L., Ni B., Lin H., Zhang M., Li X., Yin X., Qu C., Ni J. Traditional usages, botany, phytochemistry, pharmacology and toxicology of Polygonum multiflorum Thunb.: a review. J. Ethnopharmacol. 2015, 159:158-183.
112. Loretti A.P., Colodel E.M., Gimeno E.J., Driemeier L. Lysosomal storage disease in Sida carpinifolia toxicosis: an induced mannosidosis in horses. Equine Veterinary J. 2003, 35:434-488.
113. Ludolph A.C., Hugon J., Dwivedi M.P., Schaumburg H.H., Spencer P.S. Studies on the aetiology and pathogenesis of motor neuron diseases. Lathyrism: clinical findings in established cases. Brain 1987, 110:149-165.
114. MacGregor F.B., Abernethy V.E., Dahabra S., Cobden I., Hayes P.C. Hepatotoxicity of herbal remedies. BMJ 1989, 299:1156-1157.
115. Malek R.S., Kelalis P.P. Nephrocalcinosis in infancy and childhood. J. Urol. 1975, 114:441-443.
116. Malfitano A.M., Basu S., Maresz K., Bifulco M., Dittel B.N. What we know and do not know about the cannabinoid receptor 2 (CB2). Seminars Immunol. 2014, 26:369-379.
117. Mantan M., Bagga A., Virdi V.S., Menon S., Hari P. Etiology of nephrocalcinosis in northern Indian children. Pediatr. Nephrol. 2007, 22:829-833.
118. Massey L.K. Food oxalate: factors affecting measurement, biological variation, and bioavailability. J. Am. Diet. Assoc. 2007, 107:1191-1194.
119. Massey L.K., Roman-Smith H., Sutton R.A. Effect of dietary oxalate and calcium on urinary oxalate and risk of formation of calcium oxalate kidney stones. J. Am. Diet. Assoc. 1993, 93:901-906.
120. Mattei A., Rucay P., Samuel D., Feray C., Reynes M., Bismuth H. Liver transplantation for severe acute liver failure after herbal medicine (Teucrium polium) administration. J. Hepatol. 1995, 22:597.
121. Mattocks A.R. Toxicity of pyrrolizidine alkaloids. Nature 1968, 217:723-728.
122. Mattocks A.R., Bird I. Pyrrolic and N-oxide metabolites formed from pyrrolizidine alkaloids by hepatic microsomes in vitro relevance to in vivo hepatotoxicity. Chem. Biol. Interact. 1983, 43:209-222.
123. Mazzanti G., Menniti-Ippolito F., Moro P.A., Cassetti F., Raschetti R., Santuccio C., Mastrangelo S. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur. J. Clin. Pharmacol. 2009, 65:331-341.
124. McMillan M., Spinks E.A., Fenwick G.R. Preliminary observations on the effect of dietary brussels sprouts on thyroid function. Hum. Toxicol. 1986, 5:15-19.
125. Mechoulam R., Hanus L., Fride E. Towards cannabinoid drugs-revisited. Prog. Med. Chem. 1998, 35:199-243.
126. Meschi T., Schianchi T., Ridolo E., Adorni G., Allegri F., Guerra A., Novarini A., Borghi L. Body weight, diet and water intake in preventing stone disease. Urol. Int. 2004, 72(1):29-33.
127. Meyer P. Thiaminase activities and thiamine content of Pteridium aquilinum, Equisetum ramossisimum, Malva parviflora, Pennisetum clandestinum and Medicago sativa. Onderstepoort J. Vet. Res. 1989, 56:145-146.
128. Min H.J., Jung K.A., Kim H.J., Kim T.H., Jung W.T., Lee O.K. Twelve cases of toxic hepatitis related to the root of Polygonum multiflorum Thunb. J. Hepatol. 2008, 48. S356 (Posters).
129. Miranda C.L., Reed R.L., Guengerich F.P., Buhler D.R. Role of cytochrome P450IIIA4 in the metabolism of the pyrrolizidine alkaloid senecionine in human liver. Carcinogenesis 1991, 12:515-519.
130. Molyneux R.J., James L.F. Locoweed intoxication: indolizidine alkaloids of spotted locoweed (Astragalus lentiginosus). Science 1982, 216:190-191.
131. Moro P.A., Cassetti F., Giugliano G., Falce M.T., Mazzanti G., Menniti-Ippolito F., Raschetti R., Santuccio C. Hepatitis from Greater celandine (Chelidonium majus L.): review of literature and report of a new case. J. Ethnopharmacol. 2009, 124:328-332.
132. National Toxicology Program The Toxicology and Carcinogenesis Studies of Emodin in F344/N Rats and B6C3F1 Mice (Report No. 01-3952) 2001, NTP technical report, NIH Publication (PP1-278).
133. Navarro V.J. Herbal and dietary supplement hepatotoxicity. Semin. Liver Dis. 2009, 29:373-382.
134. Navarro V.J., Barnhart H., Bonkovsky H.L., Davern T., Fontana R.J., Grant L., et al. Liver injury from herbals and dietary supplements in the U. S. Drug-Induced Liver Injury Network. Hepatology 2014, 60:1399-1408.
135. Noonan S.C., Savage G.P. Oxalate content of foods and its effect on humans. Asia Pac. J. Clin. Nutr. 1999, 8:64-74.
136. Nortier J.L., Martinez M.C., Schmeiser H.H., Arlt V.M., Bieler C.A., Petein M., Depierreux M.F., De Pauw L., Abramowicz D., Vereerstraeten P., Vanherweghem J.L. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N. Engl. J. Med. 2000, 342(23):1686-1692.
137. Nunn P.B., O'Brien P., Pettit L.D., Pyburn S.I. Complexes of zinc, copper, and nickel with the nonprotein amino acid L-alpha-amino-beta-methylaminopropionic acid: a naturally occurring neurotoxin. J. Inorg. Biochem. 1989, 37:175-183.
138. Nunn P.B., Lyddiard J.R., Chriostopher Perera K.P. Brain glutathione as a target for aetiological factors in neurolathyrism and konzo. Food Chem. Toxicol. 2011, 49:662-667.
139. Ogilvie D., McCollum J.P., Packer S., Manning J., Oyesiku J., Muller D.P., Harries J.T. Urinary outputs of oxalate, calcium, and magnesium in children with intestinal disorders. Potential cause of renal calculi. Arch. Dis. Child. 1976, 51:790-795.
140. Oliveira F.A., Galan D.T., Ribeiro A.M., Santos Cruz J. Thiamine deficiency during pregnancy leads to cerebellar neuronal death in rat offspring: role of voltage-dependent K+ channels. Brain Res. 2007, 1134:79-86.
141. Olney J.W., Zorumski C.F., Stewart G.R., Price M.T., Wang G.J., Labruyere J. Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinson's and Huntington's diseases. Exp. Neurol. 1990, 108:269-272.
142. Omelchenko I.A., Jain R.K., Junaid M.A., Rao S.L., Allen C.N. Neurotoxic potential of three structural analogues of β-N-oxalyl-α,β-diaminopropanoic acid (β-ODAP). Neurochem. Res. 1999, 24:791-797.
143. Pak C.Y., Britton F., Peterson R., Ward D., Northcutt C., Breslau N.A., McGuire J., Sakhaee K., Bush S., Nicar M., Norman D.A., Peters P. Ambulatory evaluation of nephrolithiasis. Classification, clinical presentation and diagnostic criteria. Am. J. Med. 1980, 69:19-30.
144. Patterson J.S., Jones M.Z., Lovell K.L., Abbitt B. Neuropathology of bovine beta-mannosidosis. J. Neuropathol. Exp. Neurol. 1991, 50:538-546.
145. Pavlović N.M. Balkan endemic nephropathy - current status and future perspectives. Clin. Kidney J. 2013, 6:257-265.
146. Pitt J.I. Chinese herbal medicines, aristolochic acid and Balkan endemic nephropathy. Occup. Environ. Med. 2011, 68:237.
147. Plat J., Mensink R.P. Food components and immune function. Curr. Opin. Lipidol. 2005, 16:31-37.
148. Pollmann W., Fenenberg W. Current management associated with multiple sclerosis. CNS Drugs 2008, 22(4):291-324.
149. Ponseti I.V., Baird W.A. Scoliosis and dissecting aneurysm of the aorta in rats fed with Lathyrus odoratus seeds. Am. J. Pathol. 1952, 28:1059-1077.
150. Pozdzik A.A., Salmon I.J., Debelle F.D., Decaestecker C., Van den Branden C., Verbeelen D., Deschodt-Lanckman M.M., Vanherweghem J.L., Nortier J.L. Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation. Kidney Int. 2008, 73:595-607.
151. Prohens J., Andújar I., Vilanova S., Plazas M., Gramazio P., Prohens R., Herraiz F.J., De Ron A.M. Swedish coffee (Astragalus boeticus L.), a neglected coffee substitute with a past and a potential future. Genet. Resour. Crop Evol. 2014, 61(1):287-297.
152. Ralphs M.H., Stegelmeier B.L. Locoweed toxicity, ecology, control and management. Int. J. Poisonous Plant Res. 2011, 1(1):47-64.
153. Ralphs M.H., Welsh S.L., Gardner D.R. Distribution of locoweed toxin swainsonine in populations of Oxytropis lambertii. J. Chem. Ecol. 2002, 28(4):701-707.
154. Ralphs M.H., Creamer R., Baucom D., Gardner D.R., Welsh S.L., Graham J.D., Hart C., Cook D., Stegelmeier B.L. Relationship between the endophyte Embellisia spp. and the toxic alkaloid swainsonine in major locoweed species (Astragalus and Oxytropis). J. Chem. Ecol. 2008, 34:32-38.
155. Rao S.L., Sarma P.S., Mani K.S., Raghunatha Rao T.R., Sriramachari S. Experimental neurolathyrism in monkeys. Nature 1967, 214:610-611.
156. Rieder S.A., Chauhan A., Singh U., Nagarkatti M., Nagarkatti P. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology 2010, 215(8):598-605.
157. Robertson W.G. Renal stones in the tropics. Semin. Nephrol. 2003, 23:77-87.
158. Robles-Diaz M., Gonzalez-Jimenez A., Medina-Caliz I., Stephens C., García- Cortes M., García-Muñoz B., et al. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Aliment Pharmacol. Ther. 2015, 41:116-125.
159. Roeder E. Medicinal plants in Europe containing pyrrolizidine alkaloids. Pharmazie 1995, 50:83-98.
160. Roeder E. Medicinal plants in China containing pyrrolizidine alkaloids. Pharmazie 2000, 55:711-726.
161. Roman G.C. Autism: transient in utero hypothyroxinemia related to maternal flavonoid ingestion during pregnancy and to other environmental antithyroid agents. J. Neurol. Sci. 2007, 262:15-26.
162. Ross S.M., Roy D.N., Spencer P.S. Beta-N-Oxalylamino-L-alanine action on glutamate receptors. Neurochem. 1989, 53:710-715.
163. Salah K.B., Mahjoub M.A., Chaumont J.P., Michel L., Millet-Clerc J., Chraeif I., Ammar S., Mighri Z., Aouni M. Chemical composition and in vitro antifungal and antioxidant activity of the essential oil and methanolic extract of Teucrium sauvagei Le Houerou. Nat. Prod. Res. 2006, 20:1089-1097.
164. Sarma D.N., Barrett M.L., Chavez M.L., Gardiner P., Ko R., Mahady G.B., Marles R.J., Pellicore L.S., Giancaspro G.I., Low Dog T. Safety of green tea extracts: a systematic review by the US Pharmacopeia. Drug Saf. 2008, 31:469-484.
165. Sarris J., LaPorte E., Schweitzer I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust. N. Z. J. Psychiatry 2011, 45:27-35.
166. Sartelet H., Serghat S., Lobstein A., Ingenbleek Y., Anton R., Petitfrère E., Aguie-Aguie G., Martiny L., Haye B. Flavonoids extracted from fonio millet (Digitaria exilis) reveal potent antithyroid properties. Nutrition 1996, 12:100-106.
167. Schiano T.D. Hepatotoxicity and complementary and alternative medicines. Clin. Liver Dis. 2003, 7:453-473.
168. Seeff L.B. Herbal hepatotoxicity. Clin. Liver Dis. 2007, 11:577-596.
169. Sgro C., Clinard F., Ouazir K., Chanay H., Allard C., Guilleminet C., Lenoir C., et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002, 36:451-455.
170. Shasi Vardhan K., Pratap Rudra M.P., Rao S.L. Inhibition of tyrosine aminotransferase by β -N-oxalyl-L-α, β-diaminopropionic acid, the Lathyrus sativus neurotoxin. J. Neurochem. 1997, 68:2477-2484.
171. Singh S.S., Rao S.L.N. Lessons from neurolathyrism: a disease of the past & the future of Lathyrus sativus (Khesari dal). Indian J. Med. Res. 2013, 138:32-37.
172. Skoulidis F., Alexander G.J., Davies S.E. Ma huang associated acute liver failure requiring liver transplantation. Eur. J. Gastroenterol. Hepatol. 2005, 17:581-584.
173. Smiley J.D., Yeager H., Ziff M. Collagen metabolism in osteolathyrism in chick embryos: site of action of β-aminopropionitrile. J. Exp. Med. 1962, 116:45-54.
174. Spencer P.S., Palmer V.S. Interrelationships of undernutrition and neurotoxicity: food for thought and research attention. Neurotoxicology 2012, 33:605-616.
175. Spencer P.S., Roy D.N., Ludolph A., Hugon J., Dwivedi M.P., Schaumburg H.H. Lathyrism: evidence for role of the neuroexcitatory amino acid BOAA. Lancet 1986, 2:1066-1067.
176. Starakis I., Siagris D., Leonidou L., Mazokopakis E., Tsamandas A., Karatza C. Hepatitis caused by the herbal remedy Teucrium polium L. Eur. J. Gastroenterol. Hepatol. 2006, 18:681-683.
177. Stefanović V., Toncheva D., Atanasova S., Polenaković M. Etiology of Balkan endemic nephropathy and associated urothelial cancer. Am. J. Nephrol. 2006, 26:1-11.
178. Stiborova A., Frei E., Breuer A., Bieler C.A., Schmeiser H.H. Aristolactam I a metabolite of aristolochic acid Iupon activation forms an adduct found in DNA of patients with chinese herbs nephropathy. Exp. Toxicol. Pathol. 1999, 51:421-427.
179. Stickel F., Patsenker E., Schuppan D. Herbal hepatotoxicity. J. Hepatol. 2005, 43:901-910.
180. Suk K.T., Kim D.J., Kim C.H., Park S.H., Yoon J.H., Kim Y.S., Baik G.H., Kim J.B., Kweon Y.O., Kim B.I., Kim S.H., Kim I.H., Kim J.H., Nam S.W., Paik Y.H., Suh J.I., Sohn J.H., et al. A prospective nationwide study of drug-induced liver injury in Korea. Am. J. Gastroenterol. 2012, 107:1380-1387.
181. Tan Y.Y., Hong Z.P., Guo Q.H., Gao J.X., Wang J.H., Li Q.F. Preliminary studies on the extraction, separation and toxicities of alkaloids from Oxytropis glacialis Benth. ex Bunge collected in Tibet. J. Anim. Toxicol. 1999, 14:22-26.
182. Tanaka T. Tanaka's Cyclopaedia of Edible Plants of the World 1976, 924 pp. first ed.
183. Taylor E.N., Curhan G.C. Oxalate intake and the risk for nephrolithiasis. J. Am. Soc. Nephrol. 2007, 18:2198-2204.
184. Teschke R., Bahre R. Severe hepatotoxicity by Indian Ayurvedic herbal products: a structured causality assessment. Ann. Hepatol. 2009, 8:258-266.
185. Teschke R., Eickhoff A. Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps. Front. Pharmacol. 2015, 6:1-40.
186. Teschke R., Schwarzenboeck A., Hennermann K.H. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur. J. Gastroenterol. Hepatol. 2008, 20:1182-1193.
187. Thomassen D., Knebel N., Slattery J.T., McClanahan R.H., Nelson S.D. Reactive intermediates in the oxidation of menthofuran by cytochromes P-450. Chem. Res. Toxicol. 1992, 5:123-130.
188. Tramer M.R., Carroll D., Campbell F.A., Reynolds D.J., Moore R.A., McQuay H.J. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. Br. Med. J. 2001, 323(7303):16-21.
189. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu. Rev. Pharmacol. Toxicol. 2007, 47:513-539.
190. Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem. Res. Toxicol. 2008, 21:84-92.
191. Utiger R.D. Maternal hypothyroidism and fetal development. N. Engl. J. Med. 1999, 341:601-602.
192. Vafeiadou K., Vauzour D., Spencer J.P.E. Neuroinflammation and its modulation by flavonoids. Endocr. Metab. Immune Disord. Drug Targets 2007, 7:211-224.
193. Vanhaelen M., Vanhaelen-Fastre R., But P., Vanherweghem J.L. Identification of aristolochic acid in Chinese herbs. Lancet 1994, 343:174.
194. Vanherweghem J.L. Aristolochia sp and chronic interstitial nephropathies in Indians. Lancet 1997, 349:1399.
195. Vanherweghem J.L., Depierreux M., Tielemans C., Abramowicz D., Dratwa M., Jadoul M., Richard C., Vandervelde D., Verbeelen D., Vanhaelen-Fastre R., et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993, 341:387-391.
196. Wai C.T., Tan B.H., Chan C.L., Sutedja D.S., Lee Y.M., Khor C., Lim S.G. Drug-induced liver injury at an Asian center: a prospective study. Liver Int. 2007, 27:465-474.
197. Wang C.F., Wu X.D., Chen M., Duan W.G., Sun L.X., Yan M., Zhang L.Y. Emodin induces apoptosis through caspase 3-dependent pathway in HK-2 cells. Toxicology 2007, 231:120-128.
198. Wang Q.X., Wu C.Q., Yang H.L., Jing S.F., Jin C., Xiao X.H., Liao M.Y. Cytotoxicity of free anthraquinone from Radix et Rhizoma Rheito HK-2 Cells. Chin. J. New Drugs 2007, 16:189-199.
199. Whitton P.A., Lau A., Salisbury A., Whitehouse J., Evans C.S. Kava lactones and the kava-kava controversy. Phytochemistry 2003, 64:673-679.
200. Wink M. Interference of alkaloids with neuroreceptors and ion channels. Bioact. Nat. Prod. 2000, 11:3-129.
201. Wink M. Evolution of secondary metabolites from an ecological and molecular phylogenetic perspective. Phytochemistry 2003, 64:3-19.
202. Wink M. Plant secondary metabolism: diversity, function and its evolution. Nat. Prod. Commun. 2008, 3:1205-1216.
203. Wu K.M., Farrelly J.G., Upton R., Chen J. Complexities of the herbal nomenclature system in traditional Chinese medicine (TCM): lessons learned from the misuse of Aristolochia-related species and the importance of the pharmaceutical name during botanical drug product development. Phytomedicine 2007, 14:273-279.
204. Xu S., Levine M. Medical residents' and students' attitudes towards herbal medicines: a pilot study. Can. J. Clin. Pharmacol. 2008, 15:1-4.
205. Yang L., Li X., Wang H. Possible mechanisms explaining the tendency towards interstitial fibrosis in aristolochic acid induced acute tubular necrosis. Nephrol. Dial. Transplant. 2007, 22:445-456.
206. Yang L., Aronsohn A., Hart J., Jensen D. Herbal hepatoxicity from Chinese skullcap: a case report. World J. Hepatol. 2012, 4:231-233.
207. Zhang C., Wang X., Shang M., Yu J., Xu Y., Li Z., Lei L., Li X., Cai S., Namba T. Simultaneous determination of five aristolochic acids and two aristololactams in Aristolochia plants by high-performance liquid chromatography. Biomed. Chromatogr. 2006, 20(4):309-318.
208. Zhu M., Phillipson J.D. Hong Kong samples of the traditional Chinese medicine 'Fang ji' contain aristolochic acid toxins. Int. J. Pharmacogn. 1996, 34:283-289.